KIMS - Krishna Institu.
📢 Recent Corporate Announcements
Shareholders of Krishna Institute of Medical Sciences (KIMS) have overwhelmingly approved a special resolution to raise funds through a Qualified Institutions Placement (QIP). The voting results show near-unanimous support, with 28.37 crore votes in favor and only 26 votes against. Public institutional investors demonstrated high conviction, casting 16.48 crore votes entirely in favor of the proposal. This approval provides the company with the necessary mandate to proceed with capital infusion for its growth or debt management strategies.
- Special resolution for equity issuance via QIP passed with 99.99% majority support.
- Total of 28,36,95,628 votes were polled during the postal ballot process ending April 15, 2026.
- Public Institutions cast 16,47,96,564 votes, representing 87.39% of their holding, all in favor.
- Promoter and Promoter Group supported the resolution with 11,06,94,350 votes in favor.
- The resolution is deemed passed as of April 15, 2026, the final date of e-voting.
Krishna Institute of Medical Sciences (KIMS) has filed its quarterly compliance certificate for the period ended March 31, 2026, as per SEBI (Depositories and Participants) Regulations. The certificate, issued by MUFG Intime India Private Limited, confirms that all dematerialization requests from shareholders were processed within the mandated timelines. It also verifies that physical security certificates were mutilated and cancelled after the name of the depositories was substituted in the register of members. This is a standard administrative filing and does not impact the company's financial or operational standing.
- Compliance certificate submitted for the quarter ended March 31, 2026.
- Issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
- Registrar MUFG Intime India confirmed all demat requests were processed within prescribed timelines.
- Physical certificates were mutilated and cancelled after verification by the depository participant.
Krishna Institute of Medical Sciences (KIMS) has announced that its subsidiary, SPANV Medisearch Lifesciences, successfully appealed a tax demand for Assessment Year 2022-23. The Income Tax Department, through the National Faceless Appeal Centre, has set aside the previous demand notice. Consequently, the total amount payable for this matter has been reduced to Rs 0. This resolution clears a potential financial contingency for the company's subsidiary.
- Income Tax Department set aside the demand notice for subsidiary SPANV Medisearch Lifesciences.
- The tax demand pertained to Assessment Year 2022-2023.
- The final amount payable in respect of this tax matter is now Rs 0.
- Order received on March 29, 2026, under Section 143(3) read with sections 250 and 144B of the IT Act.
Krishna Institute of Medical Sciences (KIMS) has announced the closure of its trading window starting April 1, 2026, in compliance with SEBI Insider Trading regulations. This closure is a standard procedure ahead of the board's consideration of audited standalone and consolidated financial results for the quarter and year ending March 31, 2026. The trading restriction applies to all directors, designated employees, and insiders until 48 hours after the results are declared. This is a routine regulatory filing and does not impact the company's fundamental operations.
- Trading window closure effective from Wednesday, April 1, 2026
- Closure is for the purpose of considering audited financial results for Q4 and FY26
- Window will reopen 48 hours after the official announcement of financial results
- Restriction applies to all Directors, Designated Employees, and their immediate relatives
Krishna Institute of Medical Sciences (KIMS) has issued a postal ballot notice to seek shareholder approval for raising capital up to ₹1,500 crore. The funds are proposed to be raised through a Qualified Institutions Placement (QIP) by issuing equity shares to institutional investors. The company may offer a discount of up to 5% on the floor price determined by SEBI regulations. The e-voting process for this special resolution is scheduled to conclude on April 15, 2026.
- Proposed fundraising of up to ₹1,500 crore through a Qualified Institutions Placement (QIP).
- Shareholder approval sought via special resolution with e-voting ending April 15, 2026.
- Company authorized to offer a discount of up to 5% on the SEBI-calculated floor price.
- Minimum 10% of the QIP securities to be allotted specifically to mutual funds.
- Allotment of shares must be completed within 365 days from the date of the resolution passing.
Krishna Institute of Medical Sciences (KIMS) has announced its participation in a group meeting with analysts and institutional investors. The event is scheduled for March 23, 2026, at the DAM Capital Hospitals & Diagnostics conference in Mumbai. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during the session. This is a routine engagement aimed at maintaining transparency with the investment community.
- Meeting scheduled for March 23, 2026, in Mumbai, India.
- Participation in the DAM Capital Hospitals & Diagnostics conference.
- The interaction is categorized as a group meeting with institutional investors.
- Company confirms no unpublished price sensitive information will be disclosed.
- Disclosure made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Krishna Institute of Medical Sciences Limited (KIMS) has announced a scheduled interaction with institutional investor Aberdeen. The meeting is slated for March 18, 2026, and will be conducted virtually via Zoom. This disclosure is a routine compliance filing under Regulation 30 of the SEBI (LODR) Regulations, 2015. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during this session.
- Virtual meeting scheduled with Aberdeen on March 18, 2026
- Interaction to be conducted via Zoom Meeting mode
- Compliance filing under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- Company confirmed no Unpublished Price Sensitive Information (UPSI) will be disclosed
Krishna Institute of Medical Sciences Limited (KIMS) has announced its participation in a group meeting with institutional investors and analysts. The event, titled 'Chasing Growth 2026', is organized by Kotak Securities and will take place in Mumbai on February 25, 2026. This disclosure is a routine regulatory filing under SEBI (LODR) Regulations, 2015. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during this interaction.
- Group meeting scheduled with analysts and institutional investors on February 25, 2026
- Participation in the 'Chasing Growth 2026' conference organized by Kotak Securities
- The meeting will be held in a physical format in Mumbai, India
- Company confirms that no unpublished price sensitive information will be disclosed
Krishna Institute of Medical Sciences Limited (KIMS) has announced a scheduled interaction with Lion Global Investors on February 19, 2026. The meeting is set to take place virtually via Zoom as part of an investor conference. This disclosure is a routine filing under SEBI Listing Obligations and Disclosure Requirements. The company explicitly stated that no unpublished price sensitive information will be shared during the meeting.
- Meeting with Lion Global Investors scheduled for February 19, 2026
- The interaction will be held through a virtual Zoom Meeting mode
- Compliance filing under Regulation 30 of SEBI (LODR) Regulations, 2015
- Company confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed
KIMS reported a record-breaking quarter with total revenue crossing ₹1,003 crores, a 29.2% YoY increase driven by aggressive expansion. However, consolidated PAT declined significantly to ₹52 crores from ₹93 crores YoY, primarily due to gestation losses from seven new hospitals launched in 2025. Management expects the Thane and Bangalore units to reach EBITDA neutrality by Q1 FY27, which should trigger margin recovery. Operational metrics remain robust with ARPOB growing 20.5% YoY, supported by high-value transplant procedures in new clusters.
- Total revenue reached ₹1,003 crores, marking a 29.2% YoY growth and crossing the ₹1,000 Cr quarterly mark for the first time.
- EBITDA margins compressed to 20.4% from 25.9% YoY due to operational costs of 7 new units launched across 5 states.
- Average Revenue Per Operating Bed (ARPOB) grew by 20.5% YoY, significantly aided by 25 transplants in the new Bangalore unit.
- Consolidated PAT fell 44% YoY to ₹52 crores, resulting in a diluted EPS of ₹1.3 compared to ₹2.16 in the previous year.
- Andhra cluster volumes were temporarily impacted by a one-month strike related to the Aarogyasri scheme, though recovery was noted in January.
Krishna Institute of Medical Sciences (KIMS) has officially released the audio recording of its Q3 FY26 earnings conference call held on February 9, 2026. This filing is a mandatory disclosure under SEBI (LODR) Regulations to ensure transparency for all shareholders. The recording provides insights into the company's financial performance and management's outlook for the upcoming quarters. Interested parties can access the file through the company's investor relations portal.
- Audio recording of Q3 FY26 investor call made available on February 9, 2026.
- Disclosure compliant with SEBI Regulation 30 and 46(2).
- Recording accessible via the KIMS official website under the 'Investors' section.
Krishna Institute of Medical Sciences (KIMS) has issued a clarification regarding its Board Meeting outcome dated February 6, 2026. The update corrects the name of the statutory auditors to S.R. Batliboi & Associates LLP from a previously misstated name. Additionally, the company corrected its shareholding in a specific disclosure from 75.53% to 75.83%. These amendments are administrative in nature and do not impact the company's financial results or operational outlook.
- Statutory auditor name corrected to S.R. Batliboi & Associates LLP
- Shareholding percentage in specific disclosure revised from 75.53% to 75.83%
- Corrections relate to the Board Meeting outcome and Reg-30 disclosure filed on February 6, 2026
- All other information from the previous filing remains unchanged
KIMS released its Q3 and 9M FY26 investor presentation, highlighting a strong growth trajectory with total revenue reaching ₹3,067 crore in FY25. The hospital network expanded significantly from 12 units in 2024 to 18 units in 2025, reflecting aggressive geographic expansion across South and West India. EBITDA grew to ₹759 crore in FY25, maintaining a robust long-term CAGR of 29.7%. The company is targeting a total bed capacity of over 9,100 beds through upcoming projects in locations like Kompally and Gachibowli.
- Total revenue grew to ₹30,670 million in FY25, representing a 26.9% CAGR since 2005
- EBITDA reached ₹7,590 million in FY25 with a healthy long-term CAGR of 29.7%
- Hospital network expanded from 12 to 18 units within a single year between 2024 and 2025
- Future roadmap targets a massive capacity of 9,100+ beds across Telangana, AP, Maharashtra, and Kerala
- Strong institutional backing with DIIs and FIIs holding a combined 49.3% stake as of December 2025
KIMS reported a strong 26.9% YoY revenue growth, crossing the ₹1,000 crore quarterly milestone for the first time. However, profitability was significantly impacted by the operationalization of new units, with PAT declining 44% YoY to ₹52 crore and EBITDA margins contracting to 20.4% from 25.9%. Operational metrics remained robust as ARPOB grew by 20.5% YoY, indicating better realization per bed. The management remains optimistic as new units in Bangalore and Thane continue to ramp up clinical and non-clinical parameters.
- Total Revenue reached ₹1,003 Cr, growing 26.9% YoY and 3.9% QoQ.
- PAT declined to ₹52 Cr from ₹93 Cr in the previous year, a 44% drop.
- EBITDA margins compressed to 20.4% compared to 25.9% in Q3 FY25 due to costs from newer units.
- ARPOB (Average Revenue Per Occupied Bed) showed strong growth of 20.5% YoY.
- The group currently operates 7,100+ beds with plans to expand to 9,100+ beds.
The Board of KIMS has approved an additional investment of up to ₹100 Crores to acquire further shares in its material subsidiary, Sarvejana Healthcare Private Limited (Sunshine Hospital). KIMS currently holds a 75.53% stake in the subsidiary, which has shown strong financial performance with turnover growing from ₹419.44 Cr in FY23 to ₹597.00 Cr in FY25. The acquisition will be executed in one or more tranches from minority shareholders via cash consideration. This strategic move aims to consolidate ownership in a key performing asset specializing in orthopedics and high-end healthcare.
- Board approved ₹100 Crore investment to buy out minority shareholders in Sunshine Hospital.
- Sunshine Hospital turnover grew 28.6% year-on-year to ₹597.00 Cr in FY25.
- KIMS currently owns 75.53% of the subsidiary and seeks to further enhance this shareholding.
- The acquisition will be funded through cash based on independent valuation reports.
- Sunshine Hospital is a key asset for KIMS, focusing on high-growth segments like orthopedics and transplants.
Financial Performance
Revenue Growth by Segment
Consolidated revenue grew 21% YoY to INR 3,039 Cr in FY25 from INR 2,503 Cr in FY24. Growth was driven by a 22% CAGR between FY20-24, supported by bed additions and improved ARPOBD. The flagship Secunderabad hospital's revenue contribution has been successfully diluted from 60% in FY18 to <35% in FY25.
Geographic Revenue Split
Telangana and Andhra Pradesh remain the core markets with 15 hospitals. Expansion is underway in Maharashtra (Nashik, Mumbai, Nagpur), Karnataka (Bengaluru), and Kerala. The Secunderabad flagship now accounts for <35% of revenue, down from 60% in FY18, indicating improved geographic diversification.
Profitability Margins
PAT margin stood at 13.6% in FY25 (INR 415 Cr) compared to 13.4% in FY24 (INR 336 Cr). Operating margins improved by 30 bps to 26.3% in FY25 from 26% in FY24. RoCE moderated to 16.5% in FY25 from 18.1% in FY24 due to aggressive front-ended capex but is expected to stabilize between 12-15%.
EBITDA Margin
Operating profitability is maintained at 25-26% as of FY25. While new greenfield hospitals in Nashik and Bengaluru may cause a temporary drag, the company expects to sustain margins above 25% due to high operational efficiency and quick turnaround of acquired assets.
Capital Expenditure
KIMS incurred INR 1,792 Cr capex in FY25 for greenfield projects in Thane and Bengaluru. Planned capex of INR 2,200-2,500 Cr is scheduled between FY26 and FY28 to add 2,000 beds and establish oncology departments.
Credit Rating & Borrowing
Long-term rating upgraded to CRISIL AA/Stable from CRISIL AA-/Positive in April 2024; short-term rating reaffirmed at CRISIL A1+. Interest coverage ratio moderated to 8.24x in FY25 from 11.99x in FY24 due to increased debt servicing requirements.
Operational Drivers
Raw Materials
Medical consumables, surgical implants, and pharmaceuticals represent the primary operational costs, though specific percentage of total cost is not disclosed in available documents.
Capacity Expansion
Current capacity is 3,975 beds as of Dec 2023. KIMS added 1,000 beds in FY25 (including 325 beds in Nashik). Planned expansion includes 1,100 beds in FY26 and another 1,000 beds across FY27-28, with a long-term target of 3,000 beds in Kerala via the O&M model.
Raw Material Costs
Not disclosed as a specific percentage of revenue; however, operating efficiencies are driven by a 3.66-day Average Length of Stay (ALOS) in FY25, down from 4.11 days in FY24, which optimizes consumable usage per patient.
Manufacturing Efficiency
Operational efficiency is reflected in high ARPOBD and 'good' occupancy levels. The group achieved a 30 bps improvement in operating margin to 26.3% in FY25 through better performance at Begumpet and Nagpur facilities.
Strategic Growth
Expected Growth Rate
15-20%
Growth Strategy
Growth will be achieved through a mix of greenfield expansions (Bengaluru hospitals starting in 3-4 months), brownfield additions (2,000 beds by FY28), and an asset-light O&M model in Kerala targeting 3,000 beds. The strategy focuses on reducing flagship dependence and expanding into high-ARPOB markets like Mumbai and Bengaluru.
Products & Services
Tertiary and quaternary healthcare services including cardiology, oncology, neurology, and multi-specialty surgical procedures.
Brand Portfolio
KIMS Hospitals, Sunshine Hospitals (Sarvejana Healthcare).
New Products/Services
Expansion into specialized Oncology departments across the hospital network is a key focus for the FY26-28 capex cycle.
Market Expansion
Entry into Bengaluru (2 hospitals in 3-4 months), Thane, and Kerala (O&M model) to diversify beyond the core Telangana/AP cluster.
Market Share & Ranking
One of the leading tertiary care players in Andhra Pradesh and Telangana; Secunderabad facility is one of the largest single-location hospitals in India with ~1,000 beds.
Strategic Alliances
General Atlantic holds a 42.6% minority stake. KIMS also uses an O&M (Operations and Management) model for expansion in Kerala to receive management fees without heavy capital outlay.
External Factors
Industry Trends
The hospital industry is seeing a shift toward regional consolidation and 'hub-and-spoke' models. KIMS is positioning itself by expanding from its Hyderabad hub into adjacent states while maintaining a high-margin tertiary care focus.
Competitive Landscape
Competes with other major multi-specialty chains in South and West India; competitive edge maintained through lower capital cost per bed and efficient turnaround of acquired assets.
Competitive Moat
The primary moat is the 'Doctor-Partnership' model which creates high switching costs for top surgeons and ensures stable clinical outcomes. This is sustainable as it aligns physician incentives with hospital profitability.
Macro Economic Sensitivity
Sensitive to healthcare spending trends and government reimbursement rates for institutional payers (CGHS/ECHS).
Consumer Behavior
Increasing preference for insurance-backed private healthcare over government facilities, with insurance and institutional payers now making up 70% of the KIMS payer mix.
Geopolitical Risks
Minimal direct impact, though global supply chains for high-end medical machinery (MRI, CT scanners) could be affected by trade barriers.
Regulatory & Governance
Industry Regulations
Subject to National Pharmaceutical Pricing Authority (NPPA) caps on medical devices/implants and state-level clinical establishment acts. Compliance with empanelment criteria for government schemes (CGHS/ECHS) is critical for volume.
Risk Analysis
Key Uncertainties
The primary risk is the successful ramp-up of 2,000 new beds. Failure to achieve optimal occupancy could lead to Debt/EBITDA exceeding the projected 3.5x in FY26, potentially impacting credit metrics.
Geographic Concentration Risk
While reducing, the company still has significant concentration in Telangana and Andhra Pradesh, making it vulnerable to regional regulatory changes or local competition.
Third Party Dependencies
High dependency on key doctors; however, this is mitigated by the equity-sharing model.
Technology Obsolescence Risk
Medical technology requires constant reinvestment; KIMS is addressing this through its INR 2,200-2,500 Cr capex plan which includes new oncology equipment.
Credit & Counterparty Risk
40% of revenue comes from government/institutional payers (CGHS/ECHS), which typically have longer receivable cycles compared to cash/insurance patients.